Nathan Theodore Connell, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
von Willebrand Diseases | 18 | 2024 | 135 | 6.260 |
Why?
|
von Willebrand Factor | 12 | 2024 | 681 | 1.530 |
Why?
|
Hematology | 6 | 2024 | 243 | 1.190 |
Why?
|
Hemophilia A | 5 | 2023 | 357 | 1.180 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 4 | 2023 | 245 | 1.140 |
Why?
|
Thrombosis | 5 | 2021 | 2955 | 1.040 |
Why?
|
Anticoagulants | 8 | 2024 | 4856 | 1.030 |
Why?
|
Hematologic Diseases | 2 | 2020 | 500 | 0.940 |
Why?
|
Venous Thromboembolism | 6 | 2022 | 1883 | 0.920 |
Why?
|
Heparin | 4 | 2021 | 1632 | 0.920 |
Why?
|
Factor XIII | 1 | 2024 | 58 | 0.900 |
Why?
|
Angiodysplasia | 1 | 2023 | 22 | 0.840 |
Why?
|
Blood Coagulation Disorders, Inherited | 1 | 2021 | 19 | 0.760 |
Why?
|
Hemoglobinuria, Paroxysmal | 2 | 2019 | 86 | 0.730 |
Why?
|
Dalteparin | 1 | 2019 | 44 | 0.660 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2020 | 187 | 0.640 |
Why?
|
Plasmacytoma | 1 | 2019 | 171 | 0.610 |
Why?
|
Pyridines | 2 | 2019 | 2885 | 0.560 |
Why?
|
Hemorrhage | 8 | 2022 | 3466 | 0.540 |
Why?
|
Complement System Proteins | 1 | 2020 | 716 | 0.540 |
Why?
|
Oxazines | 1 | 2019 | 358 | 0.540 |
Why?
|
Skull Base Neoplasms | 1 | 2019 | 276 | 0.500 |
Why?
|
Perioperative Care | 2 | 2024 | 1042 | 0.480 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2016 | 344 | 0.470 |
Why?
|
Plasma Exchange | 1 | 2015 | 160 | 0.470 |
Why?
|
Vitamin K | 1 | 2016 | 312 | 0.450 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2015 | 132 | 0.440 |
Why?
|
ADAM Proteins | 1 | 2015 | 243 | 0.440 |
Why?
|
Thiazoles | 2 | 2023 | 1528 | 0.420 |
Why?
|
Thrombocytopenia | 3 | 2021 | 1172 | 0.410 |
Why?
|
Prednisone | 2 | 2018 | 1566 | 0.390 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2024 | 2769 | 0.390 |
Why?
|
Hemostasis | 4 | 2022 | 467 | 0.380 |
Why?
|
Menorrhagia | 2 | 2022 | 59 | 0.380 |
Why?
|
Splenosis | 1 | 2011 | 4 | 0.370 |
Why?
|
Cost-Benefit Analysis | 3 | 2019 | 5531 | 0.370 |
Why?
|
Gastric Outlet Obstruction | 1 | 2011 | 55 | 0.370 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 1 | 2010 | 17 | 0.370 |
Why?
|
Heart Diseases | 1 | 2024 | 2818 | 0.360 |
Why?
|
Cryptogenic Organizing Pneumonia | 1 | 2010 | 28 | 0.360 |
Why?
|
Splenic Diseases | 1 | 2011 | 91 | 0.350 |
Why?
|
Polysaccharides | 1 | 2016 | 1017 | 0.340 |
Why?
|
Blood Transfusion | 1 | 2016 | 1307 | 0.330 |
Why?
|
Tranexamic Acid | 2 | 2022 | 174 | 0.320 |
Why?
|
Methylprednisolone | 1 | 2010 | 386 | 0.320 |
Why?
|
Dexamethasone | 2 | 2016 | 1962 | 0.320 |
Why?
|
Delivery of Health Care | 3 | 2021 | 5364 | 0.300 |
Why?
|
Liver Abscess | 1 | 2007 | 81 | 0.280 |
Why?
|
Humans | 67 | 2024 | 765926 | 0.280 |
Why?
|
Physicians | 2 | 2023 | 4591 | 0.280 |
Why?
|
Pregnancy Complications, Hematologic | 2 | 2020 | 184 | 0.270 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2010 | 645 | 0.270 |
Why?
|
Pulmonary Fibrosis | 1 | 2010 | 503 | 0.270 |
Why?
|
Mentors | 2 | 2024 | 671 | 0.270 |
Why?
|
Warfarin | 1 | 2015 | 1494 | 0.270 |
Why?
|
Klebsiella Infections | 1 | 2007 | 146 | 0.260 |
Why?
|
Cysts | 1 | 2011 | 684 | 0.260 |
Why?
|
Klebsiella pneumoniae | 1 | 2007 | 253 | 0.250 |
Why?
|
Endophthalmitis | 1 | 2007 | 262 | 0.230 |
Why?
|
Cochlear Implants | 2 | 2021 | 342 | 0.230 |
Why?
|
Markov Chains | 2 | 2019 | 971 | 0.230 |
Why?
|
Partial Thromboplastin Time | 2 | 2021 | 203 | 0.220 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4213 | 0.210 |
Why?
|
Primary Health Care | 2 | 2016 | 4736 | 0.210 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2022 | 8 | 0.200 |
Why?
|
von Willebrand Disease, Type 1 | 1 | 2022 | 5 | 0.200 |
Why?
|
Factor XI Deficiency | 1 | 2021 | 16 | 0.200 |
Why?
|
Quality-Adjusted Life Years | 2 | 2019 | 1740 | 0.190 |
Why?
|
Glucocorticoids | 1 | 2010 | 2155 | 0.180 |
Why?
|
Multiple Myeloma | 1 | 2019 | 5189 | 0.180 |
Why?
|
Blood Platelet Disorders | 1 | 2021 | 60 | 0.180 |
Why?
|
Delphi Technique | 1 | 2024 | 893 | 0.180 |
Why?
|
Tomography, X-Ray Computed | 3 | 2019 | 20690 | 0.170 |
Why?
|
Hemostatics | 1 | 2022 | 247 | 0.170 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 203 | 0.170 |
Why?
|
Cochlear Implantation | 2 | 2021 | 317 | 0.160 |
Why?
|
Thiophenes | 1 | 2023 | 570 | 0.160 |
Why?
|
Thrombocythemia, Essential | 1 | 2020 | 114 | 0.160 |
Why?
|
Remote Consultation | 1 | 2021 | 241 | 0.160 |
Why?
|
Neuroma, Acoustic | 1 | 2023 | 456 | 0.160 |
Why?
|
Transsexualism | 1 | 2022 | 210 | 0.160 |
Why?
|
Desensitization, Immunologic | 2 | 2021 | 545 | 0.150 |
Why?
|
Lymphopenia | 1 | 2021 | 298 | 0.150 |
Why?
|
Dermatofibrosarcoma | 1 | 2018 | 49 | 0.150 |
Why?
|
Factor Xa | 1 | 2019 | 165 | 0.150 |
Why?
|
Abortion, Spontaneous | 2 | 2020 | 536 | 0.150 |
Why?
|
Postpartum Hemorrhage | 1 | 2022 | 275 | 0.150 |
Why?
|
Helicobacter pylori | 1 | 2021 | 380 | 0.140 |
Why?
|
Female | 24 | 2024 | 396141 | 0.140 |
Why?
|
Helicobacter Infections | 1 | 2021 | 390 | 0.140 |
Why?
|
Live Birth | 1 | 2020 | 516 | 0.140 |
Why?
|
Heart Transplantation | 1 | 2010 | 3310 | 0.140 |
Why?
|
Sepsis | 1 | 2011 | 2603 | 0.130 |
Why?
|
Speech Perception | 1 | 2021 | 512 | 0.130 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1127 | 0.130 |
Why?
|
Morpholines | 1 | 2019 | 577 | 0.130 |
Why?
|
Hematologic Tests | 1 | 2016 | 239 | 0.120 |
Why?
|
Medical Oncology | 2 | 2019 | 2339 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2021 | 960 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 234 | 0.120 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 231 | 0.120 |
Why?
|
Fellowships and Scholarships | 2 | 2024 | 1134 | 0.120 |
Why?
|
Aminopyridines | 1 | 2019 | 576 | 0.120 |
Why?
|
Platelet Count | 3 | 2023 | 784 | 0.120 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 878 | 0.120 |
Why?
|
Rhode Island | 1 | 2015 | 351 | 0.120 |
Why?
|
Anemia, Sickle Cell | 1 | 2023 | 1063 | 0.120 |
Why?
|
Cochlea | 2 | 2021 | 848 | 0.120 |
Why?
|
Burnout, Professional | 1 | 2023 | 710 | 0.120 |
Why?
|
Neoplasms | 3 | 2019 | 22340 | 0.110 |
Why?
|
Blood Platelets | 2 | 2023 | 2464 | 0.110 |
Why?
|
Internationality | 1 | 2019 | 1007 | 0.110 |
Why?
|
Pregnancy | 5 | 2022 | 30230 | 0.110 |
Why?
|
Pyridones | 1 | 2019 | 816 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 949 | 0.110 |
Why?
|
Aging | 2 | 2022 | 8725 | 0.110 |
Why?
|
Career Choice | 1 | 2019 | 769 | 0.110 |
Why?
|
Leukocytes | 1 | 2021 | 2027 | 0.100 |
Why?
|
Drug Hypersensitivity | 1 | 2021 | 903 | 0.100 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2019 | 958 | 0.100 |
Why?
|
Adult | 16 | 2023 | 223088 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7423 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36547 | 0.090 |
Why?
|
Oxygen | 1 | 2023 | 4246 | 0.090 |
Why?
|
Blood Coagulation Tests | 2 | 2022 | 267 | 0.090 |
Why?
|
Venous Thrombosis | 1 | 2020 | 1319 | 0.090 |
Why?
|
Male | 15 | 2024 | 363815 | 0.090 |
Why?
|
Endothelium, Vascular | 1 | 2022 | 4423 | 0.090 |
Why?
|
Specialization | 1 | 2015 | 779 | 0.090 |
Why?
|
Oseltamivir | 1 | 2010 | 75 | 0.090 |
Why?
|
United States | 8 | 2023 | 72909 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2021 | 3799 | 0.090 |
Why?
|
Mastectomy | 1 | 2018 | 1848 | 0.080 |
Why?
|
Factor VIII | 2 | 2022 | 347 | 0.080 |
Why?
|
Health Care Costs | 1 | 2023 | 3241 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2019 | 1590 | 0.080 |
Why?
|
Education, Medical | 1 | 2021 | 1744 | 0.080 |
Why?
|
Recombinant Proteins | 1 | 2019 | 6491 | 0.080 |
Why?
|
Azacitidine | 1 | 2010 | 334 | 0.080 |
Why?
|
Aortic Valve Stenosis | 1 | 2021 | 2022 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2031 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3769 | 0.070 |
Why?
|
Physician's Role | 1 | 2015 | 925 | 0.070 |
Why?
|
Aged | 7 | 2024 | 171163 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2018 | 2234 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2015 | 2426 | 0.070 |
Why?
|
Internal Medicine | 1 | 2015 | 1064 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2331 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2019 | 3560 | 0.070 |
Why?
|
Medicare | 2 | 2023 | 6815 | 0.070 |
Why?
|
Administration, Oral | 1 | 2015 | 4016 | 0.070 |
Why?
|
Antidotes | 2 | 2019 | 138 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2016 | 1791 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2596 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2021 | 59496 | 0.070 |
Why?
|
Pyrimidines | 1 | 2019 | 3049 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 452 | 0.070 |
Why?
|
Pregnancy Outcome | 1 | 2017 | 2969 | 0.070 |
Why?
|
Middle Aged | 10 | 2024 | 223016 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2011 | 12973 | 0.060 |
Why?
|
Drug Resistance, Viral | 1 | 2010 | 867 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2023 | 81537 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 2010 | 865 | 0.060 |
Why?
|
Age Factors | 1 | 2021 | 18382 | 0.060 |
Why?
|
Risk Factors | 4 | 2020 | 74850 | 0.060 |
Why?
|
Bronchoscopy | 1 | 2010 | 913 | 0.060 |
Why?
|
Spleen | 1 | 2011 | 2294 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9443 | 0.060 |
Why?
|
Cardiology | 1 | 2015 | 1696 | 0.060 |
Why?
|
Models, Statistical | 1 | 2018 | 5088 | 0.050 |
Why?
|
Anxiety | 1 | 2018 | 4669 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3109 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5691 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3231 | 0.050 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2022 | 87 | 0.050 |
Why?
|
Oxyhemoglobins | 1 | 2023 | 213 | 0.050 |
Why?
|
Thrombopoietin | 1 | 2023 | 225 | 0.050 |
Why?
|
Epistaxis | 1 | 2022 | 119 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6306 | 0.040 |
Why?
|
Facial Nerve | 1 | 2023 | 277 | 0.040 |
Why?
|
Electronics | 1 | 2021 | 314 | 0.040 |
Why?
|
Prothrombin Time | 1 | 2020 | 117 | 0.040 |
Why?
|
Oximetry | 1 | 2023 | 458 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2021 | 404 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2016 | 8924 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2021 | 405 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2023 | 548 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1539 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2020 | 411 | 0.040 |
Why?
|
Asia | 1 | 2021 | 630 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2018 | 5836 | 0.040 |
Why?
|
Biopsy | 1 | 2010 | 6766 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2010 | 1926 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 427 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 131 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2019 | 144 | 0.040 |
Why?
|
Depression | 1 | 2018 | 8223 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2010 | 3053 | 0.040 |
Why?
|
Lactation Disorders | 1 | 2017 | 14 | 0.040 |
Why?
|
Enoxaparin | 1 | 2020 | 390 | 0.040 |
Why?
|
Health Services | 1 | 2023 | 756 | 0.040 |
Why?
|
Nurse-Patient Relations | 1 | 2018 | 101 | 0.040 |
Why?
|
Geography | 1 | 2019 | 651 | 0.040 |
Why?
|
Stress, Mechanical | 1 | 2022 | 1670 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 600 | 0.040 |
Why?
|
Reference Standards | 1 | 2021 | 1011 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2021 | 1605 | 0.030 |
Why?
|
Risk Assessment | 1 | 2018 | 24275 | 0.030 |
Why?
|
Gender Identity | 1 | 2022 | 766 | 0.030 |
Why?
|
Fibrinogen | 1 | 2020 | 895 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2017 | 570 | 0.030 |
Why?
|
Fetal Death | 1 | 2017 | 434 | 0.030 |
Why?
|
Estradiol | 1 | 2022 | 1947 | 0.030 |
Why?
|
Health Plan Implementation | 1 | 2018 | 337 | 0.030 |
Why?
|
Mutation | 1 | 2020 | 30192 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2023 | 3733 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2024 | 65194 | 0.030 |
Why?
|
Melphalan | 1 | 2016 | 425 | 0.030 |
Why?
|
Consensus | 1 | 2024 | 3202 | 0.030 |
Why?
|
Research | 1 | 2023 | 1974 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 26282 | 0.030 |
Why?
|
Antithrombins | 1 | 2016 | 295 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1971 | 0.030 |
Why?
|
Blood Coagulation | 1 | 2019 | 1171 | 0.030 |
Why?
|
Telomerase | 1 | 2017 | 749 | 0.020 |
Why?
|
Electrodes, Implanted | 1 | 2016 | 834 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2023 | 2077 | 0.020 |
Why?
|
Leiomyoma | 1 | 2016 | 644 | 0.020 |
Why?
|
Infertility, Female | 1 | 2017 | 763 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8724 | 0.020 |
Why?
|
Drug Costs | 1 | 2019 | 1194 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 21069 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2232 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2021 | 2530 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3851 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2023 | 15802 | 0.020 |
Why?
|
Motivation | 1 | 2018 | 2018 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2749 | 0.020 |
Why?
|
RNA | 1 | 2017 | 2716 | 0.020 |
Why?
|
Caregivers | 1 | 2019 | 2304 | 0.020 |
Why?
|
Ultrasonography | 1 | 2020 | 5987 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9351 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13631 | 0.020 |
Why?
|
Communication | 1 | 2021 | 3908 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14643 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10727 | 0.020 |
Why?
|
Mass Screening | 1 | 2021 | 5449 | 0.020 |
Why?
|
Logistic Models | 1 | 2019 | 13273 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8522 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13614 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8037 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15878 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2018 | 4527 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7473 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10810 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 21513 | 0.010 |
Why?
|
Animals | 2 | 2011 | 168735 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8346 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8721 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41680 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 54807 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 5186 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29890 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2017 | 26380 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39228 | 0.010 |
Why?
|
Child | 1 | 2021 | 80568 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88811 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 59857 | 0.010 |
Why?
|